Photo: UW Health
Nov. 20, 2026 — A brain imaging marker used for years by researchers at the University of Wisconsin School of Medicine and Public Health is moving into the hands of doctors to treat patients, following recent U.S. Food and Drug Administration approval, marking an important step in how Alzheimer’s disease is evaluated in patients.
Wisconsin researchers were among the earliest adopters of the brain imaging agent, called MK-6240, and now marketed as TAUKLARIFY. The agent allows clinicians and researchers to visualize the buildup of tau, a protein closely associated with Alzheimer’s disease. Data generated through years of research at UW helped provide critical evidence supporting the agent’s FDA approval.
Definitive Alzheimer's Diagnosis
A generation ago, Alzheimer’s disease could only be definitively diagnosed after death if an autopsy revealed two abnormal proteins — beta amyloid and tau – had morphed into malformed clumps in the brain. Postmortem diagnosis is of little use, so researchers worldwide pursued imaging that could be used in living patients. The first breakthrough 20 years ago was a positron emission tomography, or PET, tracer that visualizes beta amyloid plaque in the brain, followed by another tracer for tau tangles about a decade later.
“For years, we could only see the effects of Alzheimer’s disease after symptoms appeared,” said Dr. Nate Chin, medical director of the Wisconsin Alzheimer’s Disease Research Center and associate professor of medicine at the UW School of Medicine and Public Health. “Now, with amyloid and tau imaging, we can better understand what is happening in the brain while the disease is unfolding. That information can help us diagnose patients more accurately, determine where they are in the disease process and make more informed treatment decisions.”
MK-6240 was evaluated carefully through years of collaboration among researchers at the Wisconsin Alzheimer’s Disease Research Center, the Cyclotron Research Group within the Department of Medical Physics and the Brain Imaging Core at the Waisman Center. Because the tracer contains a radioactive isotope that decays quickly, the medical school’s cyclotron and expertise in nuclear physics were key.
The ability to manufacture the tracer on demand, often daily, was critical to advancing research, according to Sterling Johnson, associate director of the Wisconsin Alzheimer’s Disease Research Center and professor of medicine at the UW School of Medicine and Public Health.
“Few institutions have the expertise and infrastructure needed to produce a tracer like this on a routine basis,” he said. “The partnership between our teams across the university has enabled studies that would not otherwise be possible and has helped position UW as a leader in this area of research.”
Funding from the National Institutes of Health, which started in 2017, sustained UW studies investigating the tracer’s potential to diagnose, Johnson said.
Tobey Betthauser, assistant professor of medicine, and Bradley Christian, professor of medical physics, both at the UW School of Medicine and Public Health, led one of the first teams in the United States to test MK-6240 while imaging the brains of research volunteers. Their 2018 study was among the first to show that the substance could accurately image tau pathology in the brain, according to Betthauser.
“The ability to track tau in the living brain over time is helping us better understand how Alzheimer’s disease develops and progresses,” he said. “As we learn more about how tau, amyloid and other pathologies interact, we move closer to understanding why symptoms emerge differently from person to person.”
A study published in 2020 in the journal Brain showed how MK-6240 is a powerful tool for gaining a fuller view of how tau and amyloid together are linked to cognitive decline. Conducted on 167 volunteers in the long-running Wisconsin Registry for Alzheimer’s Prevention, or WRAP, study, it allowed scientists to show a link between rising tau and beta amyloid levels and declining thinking, learning and memory capabilities. The study sparked additional research at UW and elsewhere to test how MK-6240 could be used.
To date, UW researchers have performed more than 2,200 scans using the tracer across 800 to 900 research volunteers and patients. The Wisconsin experts generated more data on MK-6240 than almost any other site in the world. These insights were key to moving the tracer from bench to bedside, according to Johnson.
“It is tremendously rewarding to see a tracer we helped advance from its earliest human studies become an FDA-approved diagnostic agent and move closer to clinical use for patients and clinicians across the country,” he said.
Drugs targeting tau are currently in development, and researchers are using tau PET imaging in clinical trials to sort out which patients may benefit most from experimental treatments and whether therapies are having their intended effect, according to Betthauser.
“There is a lot of emphasis on tau PET imaging in clinical trials because several anti-tau drugs are being developed,” he said. “Researchers want to know whether a therapy is effectively reaching its target and whether it is altering the disease process in the brain.”
A commercial launch timeline for MK-6240 has not yet been announced by the companies bringing it to market, but UW Health is preparing for its use in geriatric memory clinics by establishing a clinical tau PET program with input from clinicians in geriatrics, neurology and radiology, including experts trained to interpret tau PET brain scans, dedicated imaging capabilities, and clear steps for connecting patients with a team of specialists, according to Dr. Robert Przybelski, director of UW Health Geriatric Memory Clinics, and professor of medicine and psychiatry at the UW School of Medicine and Public Health.
“Years of research have allowed us to build the expertise, workflows and partnerships needed to bring tau imaging into clinical care,” he said. “When MK-6240 becomes commercially available, our teams will be well positioned to integrate this technology into our memory clinics, giving providers a critical tool for accurate patient diagnosis and the assessment of response to the emerging therapies for Alzheimer’s disease and related dementias.”

October 28, 2026 